✦ LIBER ✦

A Phase I trial of weekly lomustine in patients with advanced cancer

✍ Scribed by Charles A. Koller; Carolyn C. Gorski; Robert S. Benjamin; Sewa S. Legha; Nicholas E. Papadopoulos; Carl Plager

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 374 KB
Volume: 73
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940101)73:1<236::aid-cncr2820730140>3.0.co;2-t

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced gastric cancer

✍ Kathy Christman; David Kelsen; Leonard Saltz; Peter G. Tarassoff 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

Long-term intravenous hydroxyurea infusi

Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial

✍ Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB

Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 1 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 1 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A phase I trial of topotecan and gemcita

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

✍ Weijing Sun; James P. Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth Alg 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Phase I clinical trial of weekly combine

Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors

✍ Jacob Lokich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P